Halozyme (HALO) announced that Janssen-Cilag International, a Johnson & Johnson (JNJ) company, received European Commission approval for an ...

The European Commission (EC) has approved an indication extension of Darzalex (daratumumab) subcutaneous (SC) formulation in ...

The approval follows October 2024's indication extension for daratumumab-VRd for newly diagnosed patients eligible for ASCT.

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved an indication extension of DARZALEX® (daratumumab) subcutaneous (SC) ...

Following hot on the heels of Monday’s European Commission EC approval of an indication extension for Johnson & Johnson’s ...

The addition of subcutaneous daratumumab to triplet therapy improved outcomes for certain patients with newly diagnosed ...

Johnson & Johnson has claimed FDA approval for new formulation of its blockbuster multiple myeloma drug Darzalex that cuts its dosing time to just a few minutes from hours and could help it fend ...

Daratumumab, hyaluronidase-fihj ... Hyaluronidase increases permeability of the subcutaneous tissue by depolymerizing hyaluronan, a polysaccharide found in the extracellular matrix.

DARZALEX (daratumumab) is a prescription medication used to treat multiple myeloma, a type of blood cancer. It is not a chemotherapy drug but a human IgG1k monoclonal antibody that binds strongly ...

Jensen-Munroe relapsed in 2023 and was told unfunded, $220,000-a-year drug daratumumab was her “best option”. Unable to afford that, last year she took the second option of a stem cell transplant.